1. Home
  2. NICE guidance
  3. In development

Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

In development [GID-TA10994] Expected publication date: TBC

  • Project information
  • Project documents

22732-Rozanolixizumab-for-Myasthenia-Gravis-V1.0-FEB2022-NON-CONF.pdf (nihr.ac.uk)